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The pathogenesis of synucleinopathies, common neuropathological lesions normally associated with 
some human neurodegenerative disorders such as Parkinson’s disease, dementia with Lewy bodies and 
multiple system atrophy, remains poorly understood. In animals, ingestion of the tryptamine-alkaloid-
rich phalaris pastures plants causes a disorder called Phalaris staggers, a neurological syndrome 
reported in kangaroos. The aim of the study was to characterise the clinical and neuropathological 
changes associated with spontaneous cases of Phalaris staggers in kangaroos. Gross, histological, 
ultrastructural and immunohistochemical studies were performed to demonstrate neuronal 
accumulation of neuromelanin and aggregated α-synuclein. ELISA and mass spectrometry were used 
to detect serum-borne α-synuclein and tryptamine alkaloids respectively. We report that neurons 
in the central and enteric nervous systems of affected kangaroos display extensive accumulation 
of neuromelanin in the perikaryon without affecting neuronal morphology. Ultrastructural studies 
confirmed the typical structure of neuromelanin. While we demonstrated strong staining of 
α-synuclein, restricted to neurons, intracytoplasmic Lewy bodies inclusions were not observed. 
α-synuclein aggregates levels were shown to be lower in sera of the affected kangaroos compared to 
unaffected herd mate kangaroos. Finally, mass spectrometry failed to detect the alkaloid toxins in the 
sera derived from the affected kangaroos. Our preliminary findings warrant further investigation of 
Phalaris staggers in kangaroos, potentially a valuable large animal model for environmentally-acquired 
toxic synucleinopathy.
The molecular mechanisms underlying the accumulation of intracytoplasmic α-synuclein inclusions in human 
neurodegenerative disorders, including idiopathic Parkinson’s disease (PD), PD dementia, dementia with Lewy 
bodies (DLB) and multiple system atrophy (MSA)1 remains elusive. The demonstration that the nigrostriatal-toxic 
addictive ‘street designer drug’ N-methyl- 4-phenyl-l,2,3,6-tetrahydropyridine (MPTP), structurally analogous 
to tryptamine alkaloids (TA)-derivatives produced in vivo2, leads to long-lasting parkinsonism in humans and 
monkeys3–6, highlighted the possible involvement of alkaloids in Parkinsonism syndromes, including idiopathic 
Parkinson’s disease7,8. Furthermore, MPTP and MPTP analogues, shown to cause dopaminergic diminution in 
owl monkeys9 and C57/B1 mice10, failed to cause chronic depletion of nigrostriatal dopamine in α-synuclein 
knockout mice, suggesting that α-synuclein influences alkaloids neurotoxicity11.
Phalaris toxicity (PT) affects animals at pasture, most commonly sheep but cattle and horses can also be 
susceptible to the Phalaris-derived toxins following ingestion of various Phalaris spp such as P. aquatica12–19. PT 
has been reported since the 1940’s with a worldwide prevalence12,17,20,21 and occurs in grazing animals character-
istically during a prolonged period of dry weather that precedes rainfall22. Because these are widely cultivated 
perennial pasture plants, over many decades phalaris toxicity in livestock has been important in Australia, New 
Zealand, South Africa, USA and Norway23. Outbreaks of poisoning occur worldwide at certain times of the year 
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and are limited as far as possible by management procedures such as grazing on mature pastures which are less 
toxic than young plants.
PT can manifest as a ‘sudden death’ or as a ‘staggers’ form24; and the clinical presentation of the former is 
described as either neurologic or cardiac22,24. Staggers, which affect gait and locomotion of affected animals is fur-
ther subdivided into an acute reversible or the more common lethal chronic form (also called Phalaris staggers)24. 
Sheep affected with Phalaris staggers display a more severe clinical disorder. Following introduction to Phalaris 
pastures, sheep initially display subtle neurological signs in the first three weeks25–27 progressively becoming 
more severe and pronounced after three to four months12. Neurological signs described include incoordination, 
hyper-excitability, muscle tremors, abnormal gait, thoracic and pelvic limb paresis, convulsions, recumbency, fall-
ing and death18,26. In cattle, Phalaris staggers leads to weakness, muscle tremors, ataxia and staggering associated 
with pelvic limb paresis leading to recumbency and death23,25.
Phalaris staggers affecting eastern grey kangaroos (Macropus giganteus) has been reported previously but its 
incidence remains unknown. However, it is believed to be high in certain Australian regions following exposure 
to Phalaris-rich pastures (El-Hage, unpublished work, 2017). Phalaris staggers was also reported in red kangaroos 
(Macropus rufus), wallabies (Munday, personal communication cited in22), western grey kangaroos (Macropus 
fuliginosus fuliginosus) and Tamar wallabies [(M. eugenii; Philips, unpublished work, 1984 cited in22)]. Bacci and 
colleagues described the syndrome in seven eastern grey kangaroos (Macropus giganteus) grazing Phalaris pas-
tures22. The clinical presentation resembled that seen in sheep and included the typical Phalaris-associated neu-
rological signs such as ataxia, hyper-excitability, muscle tremors, abnormal gait, paresis, convulsions, recumbency 
and death22. Furthermore, the neuropathological changes described in these kangaroos were reported to be sim-
ilar to those described in sheep affected with Phalaris staggers and included pronounced green discoloration of 
the grey matter, that appeared microscopically as intraneuronal brown pigmentation22.
It has been proposed that Phalaris staggers is caused by tryptamine alkaloids (TA) found in Phalaris species [7, 
17]; these alkaloids are structurally comparable to serotonin27, are serotonergic receptor agonists, and have a high 
affinity for serotonin receptors28. Following administration of TA to sheep, they developed clinical signs similar 
to Phalaris staggers, supporting an etiological role of these alkaloids in the pathogenesis of Phalaris toxicity29. Of 
note, failure of MPTP and MPTP analogues to deplete nigrostriatal dopamine in α-synuclein knockout mice11 
may indicate that they also interact with Phalaris-derived alkaloids in kangaroos, sheep and cattle.
In this study, we describe the presence of α-synucleinopathy and melanopathy in the nervous system of 
Phalaris staggers-affected eastern grey kangaroos. Histology, immunohistochemistry (IHC) and electron micros-
copy (EM) were applied to confirm the presence of melanin pigments in the neurons of the central nervous 
system and the enteric nervous system of eastern grey kangaroos exposed to Phalaris pastures. Of importance, 
we also show and for the first time, the presence of intracytoplasmic α-synuclein inclusions in the neurons and 
sera of these kangaroos. Finally, using a sensitive UHPLC-MS/MS method, we were unable to detect tryptamine 
alkaloids in sera of Phalaris staggers-affected eastern grey kangaroos.
Results
Clinical presentation. All Phalaris-affected EGK displayed signs of a neurologic disorder which typically 
included ataxia, head shaking, erratic hopping and generalized muscle tremors. Upon perceived threats, episodes 
of pronounced hyperexcitability were also observed.
Haematoxylin–eosin staining displays intra-neuronal pigmentation. Macroscopic examination 
of serial transverse sections of the brains and spinal cords from Phalaris-affected EGK revealed widespread and 
conspicuous gross greenish grey matter discoloration mainly affecting the cerebral cortex, thalamus, brainstem 
and spinal cord (Fig. 1). Control brains and spinal cords of the healthy unaffected EGK sourced from the archive 
collection did not display similar pigmentary abnormalities. This suggests a link between Phalaris grass ingestion 
in EGK and the gross anatomical changes because neuronal pigmentation is well documented in Phalaris staggers 
of affected sheep and other domestic animals12,18,19,30,31.
We then performed haematoxylin–eosin (H&E) staining to assess the tissue morphology of brains (Fig. 2A–M), 
spinal cords (Fig. 3A) and gastro-intestinal tract (Fig. 3B) of Phalaris-affected and unaffected EGK. Sections 
of brain (n = 15), spinal cord (n = 10) and the intestinal tract (n = 5) from all Phalaris-affected EGK displayed 
light to intense neuromelanin-like brown pigments in neurons. These pigments appeared as conspicuous and 
uniformly sized granules scattered within the cytoplasm (Fig. 2H). Of note, and in contrast to previous reports22, 
the H&E stain revealed that accumulation of pigments in the cytoplasm of neurons did not displace the nuclei of 
affected neurons nor did it alter the integrity of their cell membranes. Of note, 5 areas of each region of the brain 
were analysed. The melanin-like pigmentation was consistently observed in the same anatomical subdivisions of 
all Phalaris-affected kangaroos, typically including midbrain and brainstem as well as the dorsal horns of the spi-
nal cord. The microscopic presentation observed in phalaris-affected EGK was not seen in any of the unaffected 
EGK (Fig. 2M–P).
Special histochemical stain displays intense intra-neuronal neuromelanin-like granules. 
Special staining to substantiate neuromelanin deposits was performed as per Orchard GE32. With the exception 
of the Warthin-Starry (WS) reaction, other stains such as Fontana-Masson and Schmorl’s stains were only able 
to faintly bind to the intraneuronal granules revealed by H&E in the brains and spinal cords of Phalaris-affected 
EGK (data not shown). For visualization of the melanin-like granules in Phalaris-affected EGK with WS reac-
tion (Fig. 2), an aqueous silver nitrate solution in combination with hydroquinone reducing agent was applied 
to serial brain and spinal cord sections. WS stain relies on the ability of certain pigments, including melanin to 
bind silver ions from solution. Of importance, we elected to use WS to aid in the identification of the granules 
revealed by H&E stain due to its superior binding to melanin and neuromelanin compared to other suboptimal 
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reactions, such as Fontana-Masson and Schmorl’s stains33,34. WS stain displayed intense dark granular staining 
in Phalaris-affected EGK sometimes leading to complete obliteration of the cell cytoplasm while retaining a clear 
interface with the neuropil (Fig. 2P). WS-specific neuromelanin was confined to cell neuronal compartments. 
Moreover, WS-specific melanin was not seen in the brains of unaffected kangaroos (Fig. 2G–I). Of note, no pig-
ments were seen in the Purkinje cells of the cerebellum of Phalaris affected EGK; however, Golgi type II neurons 
were intensely stained (data not shown).
Ultrastructure confirmation of the presence of intra-neuronal neuromelanin granules. 
Intra-neuronal granules that contain neuromelanin differ biologically and structurally from melanosomes which 
are normally found in skin and hair melanocytes and are responsible for melanin synthesis35. Transmission 
electron microscopic analysis of 5 Phalaris-affected EGK (EGK 92) and control (Fig. 3C,D) displayed the usual 
morphological ‘architecture’ typically associated with neuromelanin (Fig. 3D) and similar to those found in the 
dopaminergic neurons located in the substantia nigra pars compacta36. Here, neuromelanin was observed within 
neurons and deposited as a granular type with no fibrillar or vesiculoglobular matrix normally associated with 
melanin structures37,38. Furthermore, neuromelanin bodies displayed indistinct borders, were variable in size 
and presented as lobulated forms (15, 16). Moreover, neuromelanin was associated with what appears to be lipid 
bulbs; lipofuscin-filled vacuolar structures attached to neuromelanin containing-granules (Fig. 3D)36.
Detection of α-synuclein in the brain and serum of Phalaris-affected EGK. Due to the neurologic 
signs of Phalaris staggers in EGK and the presence of high concentrations of intra-neuronal neuromelanin, known 
to be associated with early Parkinsonian syndrome39, we investigated the presence of α-synuclein in the neurons 
and sera of all Phalaris-affected EGK via immunohistochemistry, immunofluorescence and ELISA. Initially, in 
the Phalaris-affected EGK brains we investigated the presence of the neuropathological hallmarks associated 
with human Parkinson’s disease (Fig. S2), including Lewy bodies and associated Lewy neurites39 following stain-
ing with the 97/8 rabbit anti-human α-synuclein antibody. Immunohistochemistry staining with 97/8 antibody 
revealed a fine punctate to prominent diffuse perikaryal pattern in the brain and spinal cord of Phalaris-affected 
EGK but failed to show presence of the Parkinson’s disease associated pathognomonic Lewy bodies and Lewy 
neurites (Fig. 4D–L). In order to confirm the specificity of the staining for α-synuclein, we also used the MJFR1 
rabbit anti-human α-synuclein antibody raised against human recombinant full length α-synuclein and mapped 
to amino acids 118–123 (VDPDNE). MJFR1 antibody displayed dense and intense staining for α-synuclein in 
the brain and spinal cord of Phalaris-affected EGK (Fig. 4M–R). Immunofluorescence co-localisation studies 
confirmed homing of α-synuclein aggregates to neurons following double-staining with 97/8 and NeuN antibody 
(Fig. 5). Of note, the staining of the control unaffected EGK with 97/8 rabbit anti-human α-synuclein antibody 
only showed expression of endogenous α-synuclein homing to synaptic areas (data not shown). Finally, quan-
tification of neuromelanin- and α-synuclein-laden neurons levels was perfumed using imagej analysis (Figs 6, 
S3). Levels of both neuromelanin and α-synuclein in the brains and spinal cords of Phalaris-affected EGKs were 
significantly higher compared to the unaffected EGKs (p < 0.05).
We then attempted to quantify levels of α-synuclein in sera derived from Phalaris-affected EGK by ELISA 
(Fig. 7). The immunoassay relied on the use of Syn-1 antibody for immunocapture and FL140 antibody to 
specifically immunodetect α-synuclein with no cross reactivity to β- and γ-synuclein. In 3 EGK tested, serum 
α-synuclein levels were shown to be significantly lower compared to the EGK controls (p < 0.05).
Figure 1. Macroscopic appearance of brain from a Phalaris-affected eastern grey kangaroo. Transverse 
section of the brain from case EGK89 displaying conspicuous bilateral and symmetrical, greenish, grey matter 
discoloration (arrows point to areas of pigmentation). (A) Shows the oculomotor nucleus and the red nucleus. 
Substantia nigra is evident but appears unaffected. (B) Shows the pontine nucleus. Representative of all affected 
Kangaroos.
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Tryptamine alkaloids found in Phalaris spp were not detected in sera derived from kangaroos. 
Sera from Phalaris-affected EGK and control wallaby were used in an attempt to determine whether tryptamine 
alkaloids found in Phalaris grass can be detected via alkaloid liquid chromatography-electrospray ionisation mass 
spectrometry (LC-ESIMS). A selection of ten authentic tryptamines was obtained and their respective LC reten-
tion times and [M + H]+ parent ion masses (Table 1) were measured in positive ion mode, to aid analysis of the 
kangaroo samples. A first set of analytical experiments consisted of attempting to extract each of the target parent 
masses from the total ion chromatogram for each animal sample, run over the mass range m/z 150–600. Using 
this method, none of the standard tryptamines could be detected, except possibly for N,N-dimethyltryptamine 
(DMT) in samples derived from EGK and the wallaby. Although the parent ion corresponding DMT (m/z 189.14) 
was present in the EGK samples at the expected retention time of 4.97 minutes, further evidence was sought 
before the presence of this compound could be confirmed. A second set of experiments were conducted in which 
a data dependent acquisition (DDA) method was applied. The three most abundant ions within a duty cycle 
were selected for collision induced dissociation and their respective tandem mass spectra recorded. Fragment 
ions for each relevant MS/MS spectrum from EGK and wallaby samples were compared with those obtained 
experimentally from respective standards, each cross-referenced against published spectra40. This time none 
of the target tryptamines could be identified in any of the EGK samples. It is possible that the concentration 
of sample tryptamines was so low that they escaped detection using the DDA experiment. In an attempt to 
overcome such a possibility, a third and final set of experiments were conducted. These consisted of LC sep-
aration followed by targeted tandem mass spectrometry of three analytes: DMT (m/z 189.14, RT 4.97 min), 
5-methoxy-N,N-dimethyltryptamine (m/z 219.15, RT 5.05 min) and bufotenine (m/z 205.13, RT 3.37 min). In 
each of the samples analysed, both 5-methoxy-N,N-dimethyltryptamine and bufotenine were clearly absent, as 
evidenced by a lack of match between the tandem mass spectra of standard and sample over an identical retention 
time window. The results for DMT are shown in Fig. S4. In the spectrum of authentic DMT (bottom), the parent 
ion is visible at m/z 189.15, with major fragment ions at m/z 144.09, 117.08, 91.06 and 58.07. It is clear that the 
Figure 2. Photomicrographs of the microscopic lesions in the central nervous system of a Phalaris-affected 
eastern grey kangaroo. (A) Normal appearance of the brain parenchyma in the healthy EGK (case 15-11801). 
(B–D) Are higher magnification of (A). (E) Intense neuromelanin-like brown pigments in neurons observed 
on routine H&E stained sections of brain of EGK89. (F–H) Are higher magnification of (E). Representative of 
all affected Kangaroos. (I) Silver stain reaction (Warthin Starry) did not display the presence of neuromelanin 
in the healthy EGK case 15–11801. (J–L) Are higher magnification of (I). Note absence of pigments in neurons. 
(M) Extensive intracytoplasmic melanosis in cerebral cortex derived from case EGK89, revealed by Warthin 
Starry reaction stain. (N–P) Are higher magnification of (K). Representative of all affected Kangaroos.
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spectrum from the wallaby sample lacks the parent ion, and hence can be discounted. EGK samples have spectra 
containing a parent ion at nominal mass 189, but the mass defect in each differs from the authentic significantly – 
casting serious doubt on the structure of the ion. Furthermore, despite the fact that the mass spectra of the EGK 
samples contain most of the fragment ions of authentic DMT, there is a conspicuous absence of m/z 58.07 for 
each. Thus, none of the samples contained DMT at a detectable concentration.
Discussion
In this study, we describe, and for the first time, cases of α-synucleino-neuromelanopathy in eastern grey kanga-
roos associated with Phalaris poisoning. The affected animals appear to display similar signs to those described 
by Bacci and colleagues affecting kangaroos22 and sheep12,18,22,24,41 and included ataxia, generalised muscle trem-
ors, hyper-excitability, convulsions and head shaking as well as erratic hopping and flattened ears (in the case of 
kangaroos). Animals tended to display progressive gait abnormalities and pelvic limb paresis leading to collapse 
and death18,26. The above clinical presentation combined with the medical history and neuropathological find-
ings together with the knowledge that kangaroos were grazing in a Phalaris-rich region during a climatic period 
that favoured the growth of alkaloid-rich Phalaris grass12,18,22,24,41 warranted the diagnosis of Phalaris staggers. 
In agreement with previous reports, the classical gross macroscopic greenish discoloration of the brain and spi-
nal cord was observed; this presentation was exclusive to the CNS and was not observed in the kidneys of the 
affected kangaroos in contrast with previous reports22, indicating a more time-dependent chronic process allow-
ing perhaps a faster and more efficient metabolism of the alkaloids. Furthermore, routine H&E stain revealed the 
presence of perikaryal melanin-like brown pigments affecting mainly the neurons of various areas of the brain 
and spinal cord. Moreover, we show that the neurons of the submucosal plexus of intestinal tract of the affected 
animals also contained melanin-like granules. Thus, a direct effect of the alkaloids on the ENS following ingestion 
of Phalaris grass can be hypothesized, possibly an early pathologic process/ event that precedes CNS pathologic 
changes.
Of note, an emerging concept in Parkinson’s disease research is the important role of the gastrointestinal 
tract in the pathogenesis of this disorder42. Braak and colleagues hypothesized that a prion-like agent undergoes 
retrograde transport43 from the ENS to the CNS via the vagus nerve of Parkinson’s disease patients lesions in the 
enteric nervous system precede those in the central nervous system44. Furthermore, Lebouvier and colleagues 
confirmed the presence of Parkinson’s disease pathologic changes in colon biopsies, further emphasizing the 
important role played by the gut in pathogenesis45. Despite the confirmation of the neuromelanin-like structure 
Figure 3. Photomicrographs of the microscopic and ultramicroscopic lesions in the spinal cord and enteric 
nervous system of a Phalaris-affected eastern grey kangaroo. (A) Intense neuromelanin-like brown pigments 
in neurons observed on routine H&E stained sections of intestine and (B) spinal cord from case EGK89. 
Representative of all affected Kangaroos. (C) Transmission electron microscopic (TEM) analysis of healthy 
EGK (case 15-11801) did not display electron-dense neuromelanin. (D) TEM analysis reveals intra-neuronal 
electron-dense neuromelanin (red arrows) in a Phalaris-affected EGK (EGK 92) with (E) lipid bulbs (arrow) 
attached to the granule.
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Figure 4. Photomicrographs of the α-synucleinopathy in the central nervous system of a Phalaris-affected 
eastern grey kangaroo. (A) Immunohistochemical staining of healthy EGK (case 15–11801) with rabbit 
anti-human α-synuclein polyclonal IgG [97/8; 1:2000 dilution]. (B,C) Are higher magnification of (A). (D) 
Immunohistochemical staining with rabbit anti-human α-synuclein polyclonal IgG [97/8; 1:2000 dilution] 
of a Phalaris-affected EGK (EGK 92) which shows multi-shaped aggregates ranging from ovoid and fusiform 
to threadlike intensely stained structures. (E,F) Are higher magnification of (D). (G) Immunohistochemical 
staining with rabbit anti-human α-synuclein polyclonal IgG [97/8; 1:2000 dilution] of a Phalaris-affected EGK 
(EGK 59) which shows multi-shaped aggregates ranging from ovoid and fusiform to threadlike intensely stained 
structures. (H,I) Are higher magnification of (G). (J) Immunohistochemical staining with rabbit anti-human 
α-synuclein polyclonal IgG [97/8; 1:2000 dilution] of a Phalaris-affected EGK (EGK 42) which shows multi-
shaped aggregates ranging from ovoid and fusiform to threadlike intensely stained structures. (K,L) Are higher 
magnification of (J). (M) Immunohistochemical staining with rabbit anti-human α-synuclein polyclonal IgG 
[MJRF1; 1:2000 dilution] of a Phalaris-affected EGK (EGK 92) which shows multi-shaped aggregates ranging 
from ovoid and fusiform to threadlike intensely stained structures (N,O). Are higher magnification of (M).  
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of the pigments in the neurons following staining with Warthin-Starry reaction and ultrastructural assessment with 
transmission electron microscopy, we were unable to conclusively identify any of the alkaloids normally found in 
Phalaris grass in the sera of the affected kangaroos using LC-ESIMS. Although the technique used to detect alkaloids 
in sera is highly sensitive, it is possible that these toxic compounds undergo fast metabolism and/or were not present 
at a detectable level in blood. Of note monoamine oxidase (MAO) leads to the breakdown of DMT into inactivated 
compounds while β-carbolines are potent inhibitors of the enzyme MAO and prevents DMT breakdown46, and both 
DMT and β-carbolines can be detected in blood following oral ingestion (20; 21; 85). Furthermore, both DMT and 
β-carbolines are found in Phalaris grass, so we speculate that the presence of β-carbolines in Phalaris grass led to 
accumulation of DMT following inhibition of MAO in kangaroos. It is also recognized that a number of neurotrans-
mitters, including norepinephrine, epinephrine, dopamine and serotonin are degraded physiologically by MAO 
and lead to the production of deaminated metabolites detectable in urine46. It would be worthwhile conducting 
a separate LC-MS study in an attempt to detect either alkaloids via their metabolites in blood or the deaminated 
metabolites in urine of kangaroos affected with Phalaris staggers.
A significant finding reported here is the presence of α-synucleopathy in the brains and spinal cord of 
Phalaris-affected EGK. α-synuclein appeared as multi-shaped aggregates ranging from ovoid and fusiform 
to threadlike intensely stained structures. These presentations have been described previously by others and 
are believed to represent the aggregated neurotoxic species of α-synuclein47–51. Of note, α-synuclein was not 
restricted to the substantia nigra pars compacta but was widely distributed in several areas of the brain and 
spinal cord and affecting mainly morphologically normal neurons and closely associated with neuromelanin. 
This widespread expression might reflect an acute presentation following Phalaris poisoning akin to a stress 
response. Nevertheless, the ectopic perikaryal localization of α-synuclein, a cytoplasmic, presynaptic pro-
tein52–55, away from axon terminals, together with the abnormal multi-shaped deposits is potentially a causative 
effect of the alkaloids. The multi-location of abnormal α-synuclein in synucleinopathies is widely recognized 
and reviewed in1. An important report by Hirsch and colleagues demonstrated that neuronal loss of the mid-
brain dopamine-containing cell groups directly correlated with levels of neuromelanin in PD56. Halliday and 
colleagues demonstrated that pathologic change-free-morphologically-normal dopaminergic neurons (A9 neu-
rons) in patients with early but definite Parkinson’s disease displayed higher levels of neuromelanin with its lipid 
component containing α-synuclein39; in contrast A9 neurons derived from late stage Parkinson’s disease with 
pronounced Lewy body pathologic change displayed significant loss of neuromelanin39. The Authors concluded 
that the changes observed were a prelude to the pathologic findings seen in later stages of the disorder39. The 
intracellular changes observed in the neurons of these kangaroos might reflect a similar progression but whether 
this is the case needs further confirmation. Finally, levels of α-synuclein aggregates were shown to be lower in sera 
derived from Phalaris-affected kangaroos when compared to healthy and unaffected EGK. Despite the inconsist-
ency of the previously reported results linking plasma/serum α-synuclein levels with Parkinson’s disease severity/
progression, it is generally accepted that these are decreased in this disorder57. Our results are consistent with 
previous studies that used blood samples derived from cases of Parkinsonism (reviewed in58).
In this report, we described cases of synucleinopathies in Eastern Grey Kangaroos following ingestion of 
neurotoxic, alkaloid-rich Phalaris. The kangaroos exhibited signs of a progressive neurologic disorder associated 
with neuropathologic changes that included accumulation of α-synuclein aggregates and neuromelanin without 
affecting the normal cell morphology. This study failed to demonstrate the presence of typical neuropathologic 
changes associated with Parkinson’s disease, namely Lewy bodies and Lewy neurites, probably reflecting an acute 
onset in the synucleinopathies spectrum. Further studies in kangaroos, following chronic poisoning with alka-
loids, are needed to assess their long-term effects.
Materials and Methods
Humans, animals and ethics statement. Phalaris-affected kangaroos. Nine juvenile or adult Eastern 
Grey Kangaroos (EGKs, Macropus giganteus) (Table 2) were submitted for routine teaching/diagnostic post-mor-
tem examination to UoM Veterinary Diagnostic Pathology and as such are not subject to animal ethics guidelines. 
All affected EGK animals were from various rural areas in the state of Victoria, Australia. All EGKs were graz-
ing on Phalaris pastures in May 2016 when weather conditions were reported to favour rapidly growing young 
Phalaris grass (that is, a prolonged dry spell followed by heavy rain; Fig. S1).
Unaffected kangaroos. Ten juvenile or adult Eastern Grey Kangaroos (EGKs, Macropus giganteus) (Table 2) were 
submitted for routine clinical examination to the Sydney Metropolitan Wildlife Services (sera; n = 5) and for 
routine diagnostic post-mortem examination to the New South Wales Department of Primary Industries (brains; 
n = 5) and as such are not subject to animal ethics guidelines. Sera derived from blood samples taken from the lat-
eral tail vein of five healthy unaffected EGK (Table 2), were used to compare the levels of α-synuclein aggregates. 
Brain sections derived from five healthy unaffected EGK (Table 2), were also used. All unaffected EGK animals 
were from various rural areas in the state of NSW, Australia.
Parkinson’s disease and control human samples. The human Parkinson’s disease and control brain samples were 
provided by the Victorian Brain Bank which operates under the jurisdiction of the Human Research Ethics 
(P) Immunohistochemical staining with rabbit anti-human α-synuclein polyclonal IgG [MJRF1; 1:2000 
dilution] of a Phalaris-affected EGK (EGK 59) which shows multi-shaped aggregates ranging from ovoid and 
fusiform to threadlike intensely stained structures. (Q,R) Are higher magnification of (P). Representative of all 
affected kangaroos.
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Figure 5. Immunofluorescence co-localisation of α-synuclein aggregates and neuron-specific nuclear protein, 
NeuN: Cortical co-staining with rabbit anti-human α-synuclein polyclonal IgG [97/8; 1:2000 dilution] 
(GREEN) and anti-mouse NeuN monoclonal IgG (Millipore, 1:2000 dilution) (RED) of phalaris-affected 
EGK92. DAPI (BLUE) was used to stain the nuclei. Representative of all affected kangaroos.
Figure 6. Quantitation of neuromelanin- and α-synuclein-laden neurons in Phalaris-affected and unaffected 
EGKs. Neuromelanin and α-synuclein staining levels of Phalaris-affected (n = 8) EGKs in cerebrum, mid-
brain, cerebellum and spinal cord. The data are mean ± SEM from 5 randomly selected images per section. 
Similar regions from unaffected (n = 4) EGKs were used as a control. Neuromelanin and α-synuclein staining 
levels were quantified via ImageJ software as the relative intensity of neuromelanin (*p < 0.05) and α-synuclein 
(*p < 0.05) of all combined regions in Phalaris-affected over unaffected EGK’s.
Figure 7. Immunodetection of Phalaris-associated α-synuclein by ELISA. Serum α-synuclein Average levels 
of α-synuclein in Phalaris-affected kangaroos (EGK89; EGK90 and EGK91; n = 3) were compared with average 
levels of α-synuclein in control healthy EGKC (n = 5). Error bars represent the mean level derived from n = 3 
wells.









Tyramine C8H11NO 138.0919 ND
5-Methyltyramine C9H13NO 152.1075 6.21
Tryptamine C10H12N2 161.1079 5.04
Gramine C11H14N2 175.1235 4.72
Hordenine C10H15NO 166.1232 2.82, 3.06?
Bufotenine C12H16N2O 205.1341 3.37
N-N-Dimethyltryptamine C12H16N2 189.1392 4.97
5-Methoxy-N,N-
dimethyltryptamine C13H19N2O 219.1497 5.05
5-Methyltryptamine C11H14N2 175.1235 Not actually part of the mixture!
5-Methoxytryptamine C11H14N2O 191.1184 5.10
Continued
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Committee of UoM, Ethics ID: 1545740 - Victorian Brain Bank - Brain banking for neuroscience research and 
The Victorian Institute of Forensic Medicine Ethics ID: EC12/2016 - Victorian Brain Bank (VBB). Brain Banking 
for Neuroscience Research – Studies on Neurological and Psychiatric illness. All samples where de-identified and 
coded prior to handling.
Clinical investigations. All the EGK found in Victoria displayed signs of ataxia and the majority exhibited 
other neurological signs including erratic hopping, flaccid ears, generalised muscle tremors and head shaking. 
The animals displayed signs of hyperexcitability when frightened and tended to hop erratically with complete 
failure to coordinate movements leading to falls and inability to stand. All animals were submitted for diagnostic 
investigation, including macroscopic and histological assessments.
Histopathology and immunohistochemistry. The brains of the EGK and wallaby found in Victoria 
were sectioned into two halves; the left half was frozen at −80 °C and the right half was fixed by immersion in 
10% neutral buffered formalin. Tissue slices from different anatomical regions of the cerebrum, midbrain and 
cerebellum as well as the intestinal tract were then processed through graded alcohols and xylene and embedded 
in paraffin. The tissues were sectioned at 4 µm for staining with haematoxylin and eosin (H&E), Warthin-Starry, 
Fontana-Masson, Shmorl’s or immunohistochemistry (IHC) using anti-α-synuclein antibody. Staining for 
α-synuclein was performed as described59. Serial sections were first deparaffinised then treated with 80% for-
mic acid for 5 min. This was followed by adding 3% hydrogen peroxide to block endogenous peroxidase activ-
ity. Sections were then stained with the 97/859 or MJRF1 (abcam, ab138501) rabbit anti-human α-synuclein 
polyclonal IgG [97/8; 1:2000 dilution], for 1 h at room temperature. Visualization of antibody binding was 
achieved using the LSAB™ kit (labelled streptavidin–biotin, DAKO) and sections were then incubated with 
hydrogen-peroxidase–diaminobenzidine (H2O2–DAB) to visualize α-synuclein. Sections were counterstained 
with Mayer’s haematoxylin. Sections were then viewed using a light microscope (Olympus BH-2) and scanned 
using a Zeiss Mirax Digital Slide Scanner (Zeiss). Digital images were taken from e-slides using the Pannoramic 
Viewer software analysis (3DHISTECH).
Image quantification. To quantify neurons displaying accumulation of neuromelanin or α-synuclein, sig-
nal intensity was visualised by capturing field images by Olympus VS 120 Slide Scanner and images were ana-
lysed by ‘Olympus OlyVIA’ software. Neuromelanin- or α-synuclein-laden neurons were quantified by an image 
processing software, Image J. The mean colour threshold of ‘particles’ was calculated in several brain regions 
[cerebrum (=5), midbrain (n = 5) and cerebellum (n = 5)] and spinal cord (n = 5) of each Phalaris-affected and 
unaffected kangaroos obtained with a 40 × objective, numerical aperture 0.95. The final result was presented as 
percentage intensity and expressed as mean ± S.E.M.
Immunofluorescence staining and imaging of α-synuclein aggregates and NeuN. Brain sec-
tions were processed as described above prior to staining with rabbit anti-human α-synuclein polyclonal IgG 
[97/8; 1:2000 dilution] or anti-mouse NeuN IgG monoclonal antibody (Millipore, 1:2000 dilution), for 1 h at 
room temperature. After washing, this was followed by the secondary antibody diluted in PBS [(anti-rabbit IgG 
whole molecule FITC-conjugate produced in goat, Sigma and anti-mouse IgG (H + L) Texas-red-conjugate pro-
duced in Donkey, Sigma respectively)] for 1 hour at RT.
After the final wash in PBS, fluorescence anti-fade solution (Invitrogen) was added to slides and coverslips were 
mounted and sealed with clear nail polish to prevent dehydration. Florescence microscopy was performed with a 
Leica DM4000B microscope. Images from each source [FITC (450–490 nm), and Texas red (510–560 nm)] were 
collected by a high resolution DC500 colour camera attached. All images are saved digitally using Leica’s IM500 
Image Manager Database software from the same field-of-view. Images were merged using Photoshop 6.0 (Adobe). 
Confocal laser scanning microscopy was performed with a Zeiss LSM510 confocal system on an inverted Zeiss 
Axio100M. Z-series and snapshot images were collected. Dual scans were merged using Photoshop 6.0 (Adobe).
Electron microscopy. The formalin-fixed cerebral cortex derived from a Phalaris-affected EGK and the con-
trol wallaby were fixed in 2.5% glutaraldehyde (ProSciTech, Australia) then washed in phosphate buffer and post 









β-carboline C12H14N2O 203.1184 5.40
2-Methyl-1,2,3,4-tetrahyro-
β-carboline C12H14N2 187.1235 5.68
Table 1. Selection of ten authentic tryptamines alkaloids derived from Phalaris grass (provided by Dr Larry 
Walker).
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in Spurr’s resin (ProSciTech, Australia). One-micron semi-thin sections were stained with methylene blue for 
light microscopy. Ultrathin sections were double stained with uranyl acetate and Reynold’s lead citrate and exam-
ined with a Philips CM10 transmission electron microscope at 60 kV.
Sandwich eLiSA for the detection of α-synuclein in sera of Phalaris-affected kangaroos. The 
assay was performed as described with slight adaptation60. A 384 well plate (Black, Maxisorp; Nunc) was coated 
with an IgG1 mouse anti-α-synuclein monoclonal antibody (0.25 μg/ml); Syn-1 (BD Bioscience) in 200 mM 
NaHCO3 coating buffer, pH 9.6 (50 μl/well) overnight at 4 °C. The plates were then washed four times with PBST 
(PBS containing 0.05% Tween-20) and subsequently blocked with 100 μl/well of gelatine blocking buffer (PBS 
containing 2.25% gelatine and 0.05% Tween-20) for 2 hr. at 37 °C. The plates were then washed four times with 
PBST. 50 μL of serum samples (1:4 dilution) derived from the Phalaris-affected (Victoria) and the unaffected 
(NSW) EGK as well as standards diluted in signal boost solution 1 (Signal Boost Immunoreaction Enhancer Kit, 
Merck) were then added to each well, and incubated overnight at 4 °C. The plates were then washed four times 
with PBST followed by the addition of 50μl/well of IgG anti-α/β/γ-synuclein rabbit polyclonal antibody (FL-140) 
(Santa Cruz Biotechnology, diluted to 1:1000 in Signal Boost solution 1) and incubated at 37 °C for 1.5 hours. The 
plates were then washed four times, then incubated for 1 hour at 37 °C with 50 μl/well with goat anti-rabbit horse-
radish peroxidase (Jackson Immunoresearch) diluted 1:10000 in Signal boost solution 2 (Merck). Finally, plates 
were washed again and 50 μl/well of an enhanced chemiluminescent substrate (Super-Signal ELISA Femto, Pierce 
Biotechnology) was added. Chemiluminescence in relative light units was immediately measured with a Victor3 
1420 (Wallac) microplate reader at 470 nm. Purified recombinant α-synuclein (Monash University protein unit) 
was used as standards and samples were assayed in duplicate.
Mass spectrometry. Phalaris alkaloid standards (Table 1) were sourced from Southern Scientific, 
Hamilton, Victoria, Australia and included tyramine, tryptamine, gramine, hordenine, bufotenine, 
N,N-dimethyltryptamine, 5-methyltyramine, 5-methoxytryptamine, 5-methoxy-N,N-dimethyltryptamine, 
6-methoxy-1,2,3,4-tetrahydro-β-carboline, and 2-methyl-1,2,3,4-tetrahydro-β-carboline in methanolic solution. 
Dilution in LC-MS grade acetonitrile (Burdick and Jackson) to approximately 10 ppm component concentra-
tion was performed prior to LC-MS analysis. 20 µL of each serum sample derived from Phalaris-affected EGK 
and control wallaby was added to 60 µL LC-MS grade acetonitrile to precipitate total protein content. Following 
centrifugation of the solution at 14,000 rpm for 10 min, the supernatant was carefully placed in a Waters Total 
Recovery chromatography sample vial for analysis.
Liquid chromatography was performed using a Waters Acquity UPLC equipped with a Waters Acquity 
C18 HSS column of dimensions 2.1 × 150 mm, thermostatted to 35 °C. Solvent A consisted of ultrapure water 
(Milli-Q) plus 0.1% formic acid and solvent B consisted of LC-MS grade methanol (Burdick and Jackson) plus 
0.1% formic acid. A 20 min run was employed with a flowrate of 0.20 mL/min. An initial solvent composition of 
5% B was ramped linearly to 100% B over 10 minutes. After 15 minutes the solvent composition was immediately 
returned to 5% B and maintained until the end of the run. Injections of 5 µL were made from sample solutions 
stored at 4 °C.
Mass spectrometry was performed using a Waters Xevo QToF-MS spectrometer fitted with an electrospray 
ionisation probe and operating in positive ion mode. Mass accuracy was maintained by infusing at 5 µL/min 
a lock spray solution of 200 pg/µL leucine encephalin in 50% aqueous acetonitrile, plus 0.1% formic acid, cal-
ibrated against a sodium iodide solution. The capillary voltage was maintained at 2.3 kV, cone voltage at 25 V, 
desolvation temperature 350 °C, ion block temperature 120 °C, gas (N2) flows: desolvation 450 L/hr., cone gas 
Case No. Year Month Location Victoria/NSW Species Age Category Sex Weight (Kg) Clinical Signs*
PHALARIS AFFECTED EGK
EGK89 2016 May Longlea, VIC EGK* Adult Male 12.35 Ataxia
EGK90 2016 May Taradale, VIC EGK Adult Female 15 Ataxia, ears flaccid, head shaking, ‘pogo stick’ hopping
EGK91 2016 May Taradale, VIC EGK Sub Adult Female 12 Ataxia, erratic hopping
EGK92 2016 May Taradale, VIC EGK Sub Adult Male 10.8 Ataxia, erratic hopping
EGK46 2016 May Sedgwick, VIC EGK Adult Female 15 Ataxia
EGK59 2016 May Springfield, VIC EGK Adult Female 15 Ataxia, ears flaccid
EGK53 2016 May Victoria, VIC EGK Adult NR NR Ataxia
EGK42 2016 May Victoria, VIC EGK Adult NR NR Ataxia
UNAFFECTED EGK AND SWAMP WALLABY





EGKC1 2018 July Colyton, NSW EGK Young Male 4 None
EGKC2 2018 July Colyton, NSW EGK Young Female 4 None
EGKC3 2018 July Camden, NSW EGK Young Male 5 None
EGKC4 2018 July Blacktown, NSW EGK Young Female 10 None
EGKC5 2018 July Plumpton, NSW EGK Young Male 8 None
Table 2. Clinical and epidemiological description of cases of kangaroos affected with Phalaris alkaloids and the 
Victoria regions and description of the unaffected control EGK from the NSW regions.
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10 L/hr. MassLynx software (Waters) was used to process the data. Three different types of LC-MS experiments 
were performed: (i) a simple acquisition over the mass range m/z 150–600, scan time 1 s; (ii) a targeted MS/MS 
of three analytes: m/z 205.1 (bufotenine), m/z 219.1 (5-methoxydimethyltryptamine), and m/z 189.1 (dimethyl-
tryptamine), each with a scan time of 0.5 s. Collision energy was ramped from 10–40 eV and MS/MS spectra were 
recorded over the range m/z 50–600; and a data dependent acquisition (DDA) experiment. Parent ion survey (1 s 
scan time) with mass range m/z 150–600, and fragment ion mass range m/z 50–600. Singly charged ions above 
50 cps intensity were fragmented for 2 s with a collision energy range of 10–35 eV (low mass) to 15–40 eV (high 
mass). A total of 3 ions were selected within a given scan, and after fragmentation excluded from detection for 
30 s.
Statistical analysis. One-way ANOVA with Dunnett’s post-test was performed using GraphPad Prism ver-
sion 7.00 for Windows, GraphPad Software, San Diego California USA, for statistical analysis.
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